MyMD Pharmaceuticals (MyMD Pharmaceuticals) Cash-to-Debt : 48.19 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is MyMD Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. MyMD Pharmaceuticals's cash to debt ratio for the quarter that ended in Mar. 2024 was 48.19.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, MyMD Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for MyMD Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

MYMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04 Med: 83.86 Max: No Debt
Current: 48.19

During the past 4 years, MyMD Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.04. And the median was 83.86.

MYMD's Cash-to-Debt is ranked better than
79.22% of 1535 companies
in the Biotechnology industry
Industry Median: 6.49 vs MYMD: 48.19

MyMD Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for MyMD Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

MyMD Pharmaceuticals Cash-to-Debt Chart

MyMD Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.04

77.58

34.06

100.47

MyMD Pharmaceuticals Quarterly Data
	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial											123.41	105.70	90.14	100.47	48.19

Competitive Comparison of MyMD Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, MyMD Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MyMD Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MyMD Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where MyMD Pharmaceuticals's Cash-to-Debt falls into.

MyMD Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

MyMD Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.923	/	(0.049	+	0)
	=	100.47

MyMD Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.735	/	(0.036	+	0)
	=	48.19

MyMD Pharmaceuticals (NAS:MYMD) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

MyMD Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of MyMD Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

MyMD Pharmaceuticals (MyMD Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MyMD Pharmaceuticals Inc (NAS:MYMD) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

DQS:Germany DQS:Germany

Address

855 North Wolfe Street, Suite 601, Baltimore, MD, USA, 21205

Website

https://www.mymd.com

MyMD Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. It is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-1R is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and a monoamine oxidase enzyme type B.

Executives

Paul Rivard	officer: EVP of Operations, GC	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Caroline C Williams	10 percent owner	324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Adam Kaplin	officer: Chief Scientific Officer	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Jude Uzonwanne	director	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Craig Eagle	director	POST OFFICE BOX 4590, NEW YORK NY 10163
Chapman Christopher C Jr	director, officer: President, Chief Med. Officer	C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814
Ian Rhodes	officer: Interim CFO	1375 KINGS HIGHWAY EAST, FAIRFIELD CT 06824
Stuart M Benson	officer: Chief Financial Officer	EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118
Hudson Bay Capital Management Lp	10 percent owner	28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Sander Gerber	10 percent owner	C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Robert C Schroeder	director	37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724
Howard Yeaton	officer: CEO, CFO	79 LLOYD ROAD, HOHOKUS NJ 07423
Tarbox Richard C Iii	director	AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Christopher C Schreiber	director	AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086